Respiratory Drugs News

News

ViroPharma Incorporated Buys Option to Acquire
www.biospace.com | Dec 28, 2011
EXTON, Pa. and SAN DIEGO, Dec. 22, 2011 /PRNewswire/ -- ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire

OTC codeine abuse on the rise | 6minutes
www.6minutes.com.au | Nov 7, 2011
The increasing abuse of OTC combination analgesics containing codeine and ibuprofen is causing Australian patients to present with small bowel ulceration.

New Homeopathic Products From Hyland’s Inc. Help Families Fight Coughs and Colds Naturally
www.prweb.com | Nov 2, 2011
Hyland’s Inc.'s new DEFEND Cold & Cough, DEFEND Cold & Cough Night and DEFEND Sinus offer multi-symptom relief from the symptoms of seasonal illness for adults in natural formulas that are non-drowsy and free from dyes, alcohol and sugar. Hyland’s new, 100 percent natural Baby Cough

Santarus Plans NDA Filing On Key New Drug - Seeking Alpha
seekingalpha.com | Oct 3, 2011
< strong > By < a href='http://seekingalpha.com/author/smith-on-stocks' > Smith On Stocks < /a > : < /strong > < p > < b > Investment Opinion and Overview < /b > < /p > < p > For those of you who read my recent reports on Santarus ( < a href='http://seekingalpha.com/symbol/snts' title='Santarus,

Respiratory Disorders Therapeutics Market to 2017 | PRLog
www.prlog.org | Aug 31, 2011
Respiratory Disorders Therapeutics Market to 2017. Patent Expiries and Generic Competition Are Negatively Impacting upon the Market, Reducing its CAGR from 7.7% in 2002-2010 to 3.1% in 2010-2017 - PR11642052

OXIS International Names Healthcare Industry Entrepreneur David Saloff to Board of Directors |
www.sys-con.com | Jun 30, 2011
SYS-CON Media, NJ, The world's leading i-technology media company on breaking technology news.

U.S. Asthma/COPD Market
www.frost.com | Apr 15, 2011
This research service provides an in depth analysis of factors affecting the growth of the U.S. asthma/COPD market over the period 2006-2016. Included is a disease overview, product analysis, total market revenue forecasts, product revenue forecasts, patient forecasts, and market share analysis.

Medical News: Drug Delays COPD Exacerbations - in Pulmonology, COPD from MedPage Today
www.medpagetoday.com | Mar 23, 2011
The anticholinergic agent tiotropium (Spiriva) outperformed a beta2-agonist in preventing exacerbations of chronic obstructive pulmonary disease (COPD), according to a randomized, double-bl

AstraZeneca Discontinues Pulmicort Production - Pharmaceutical Technology
pharmtech.findpharma.com | Mar 9, 2011
AstraZeneca announced this week that it will discontinue the production of Pulmicort (budesonide) 100 and 200 µg/dose HFA (hydrofluoroalkane) pressurized metered-dose inhaler (pMDI) due to manufacturing issues related to technical aspects of the device, which prevents the ongoing manufacture

Novartis | Pharma Asia
www.pharmaasia.com | Oct 6, 2010
October 12, 2010 Home About Us Current Issue Archives Events RSS Feeds More Advertising Information Editorial Information Technical Channels Drug Discovery Drug Development Drug Manufacturing Drug Delivery Clinical Trials